Bispecific Antibodies CD47 Treatment, Published 15th Apr
Summary
The European Patent Office published application EP4139364A1 on 15 April 2026, covering bispecific antibodies for treating CD47-associated diseases. Virtuoso Binco, Inc. is the applicant, with WANG, Xinhua, CHEN, Xiaocheng, SHI, Lei, POST, Leonard, and WONG, Oi Kwan listed as inventors. The application covers the CD47 pathway targeting mechanism and is classified under multiple IPC codes including C07K 16/46 and C07K 16/28. This patent provides intellectual property protection across all designated European member states including Germany, France, the United Kingdom, and 29 other designated states.
About this source
GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 58 changes logged to date.
What changed
The EPO published patent application EP4139364A1 for bispecific antibodies targeting the CD47 pathway, a mechanism associated with cancer treatment applications. The application names Virtuoso Binco, Inc. as the applicant and five named inventors. Multiple IPC classifications indicate the breadth of the technical claims including antibody engineering (C07K 16/46, C07K 16/28) and therapeutic applications (A61P 35/00 for oncology).
For pharmaceutical and biotechnology companies engaged in CD47-targeted or bispecific antibody development programs, this patent establishes prior art in the European jurisdiction. Any competing products targeting the CD47 pathway with similar bispecific configurations may require design-around strategies or licensing negotiations. The designated states list covers all major European markets, making freedom-to-operate analysis particularly important for companies planning EU market entry with CD47-related therapeutic candidates.
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
BISPECIFIC ANTIBODIES FOR TREATING CD47-ASSOCIATED DISEASES
Publication EP4139364A1 Kind: A1 Apr 15, 2026
Applicants
Virtuoso Binco, Inc.
Inventors
WANG, Xinhua, CHEN, Xiaocheng, SHI, Lei, POST, Leonard, WONG, Oi Kwan
IPC Classifications
C07K 16/46 20060101AFI20240418BHEP C07K 16/30 20060101ALI20240418BHEP A61P 35/00 20060101ALI20240418BHEP A61K 39/00 20060101ALI20240418BHEP C07K 16/28 20060101ALI20240418BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.